Volume 4, Issue 5, Pages 408-411 (June 2018) Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: Clinical approach and genetic analysis Kelly A.E. Sinx, MD, Guido M.J.M. Roemen, BASc, Virrie van Zutven, BSc, Renske Janssen, BASc, Ernst-Jan M. Speel, PhD, Peter M. Steijlen, MD, PhD, Michel van Geel, PhD, Klara Mosterd, MD, PhD JAAD Case Reports Volume 4, Issue 5, Pages 408-411 (June 2018) DOI: 10.1016/j.jdcr.2017.11.011 Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 BCNS patient. A, Before starting vismodegib. B, Clearance after 3 months of vismodegib treatment. C, BCC redevelopment (resistance). JAAD Case Reports 2018 4, 408-411DOI: (10.1016/j.jdcr.2017.11.011) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions